Evidence map›Paper›PMID 41801895›Full record

ArticleAtherosclerosis2025

Antisense oligonucleotide inhibition of HMGB1 attenuates angiotensin II-induced abdominal aortic aneurysms.

Shayan Mohammadmoradi, Hisashi Sawada, Sohei Ito, Michael K Franklin, Deborah A Howatt, Adam E Mullick, Hong S Lu, Alan Daugherty

Abstract read
In one paragraph

Article in Atherosclerosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shayan MohammadmoradiSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Saha Aortic Center, University of Kentucky, Lexington, KY, USA.
Hisashi SawadaSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Saha Aortic Center, University of Kentucky, Lexington, KY, USA; Department of Physiology, University of Kentucky, Lexington, KY, USA.
Sohei ItoSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Saha Aortic Center, University of Kentucky, Lexington, KY, USA.
Michael K FranklinSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Saha Aortic Center, University of Kentucky, Lexington, KY, USA.
Deborah A HowattSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Saha Aortic Center, University of Kentucky, Lexington, KY, USA.
Adam E MullickIonis Pharmaceuticals, Inc, Carlsbad, CA, USA.
Hong S LuSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Saha Aortic Center, University of Kentucky, Lexington, KY, USA; Department of Physiology, University of Kentucky, Lexington, KY, USA.
Alan DaughertySaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Saha Aortic Center, University of Kentucky, Lexington, KY, USA; Department of Physiology, University of Kentucky, Lexington, KY, USA. Electronic address: alan.daugherty@uky.edu.

Funding

Determinants of Aorta HeterogeneityR35HL155649 · NHLBI · UNIVERSITY OF KENTUCKY · PI Alan Daugherty · 2021 to 2026
$5.3M
Atherosclerosis Mechanisms: Angiotensin II production and actionR01HL139748 · NHLBI · UNIVERSITY OF KENTUCKY · PI DAUGHERTY, ALAN, LU, HONG SHEN · 2018 to 2021
$2.0M
NHLBI NIH HHS R01 HL139748NHLBI NIH HHS R35 HL155649
6 · The paper itself

Abstract

BACKGROUND AND

aimsVascular inflammation is a hallmark of abdominal aortic aneurysms (AAA) but the mechanism of these effects is undefined. High-mobility group box 1 (HMGB1) has potent inflammatory properties and has been implicated in various vascular diseases. We determined a role for HMGB1 in AAA pathogenesis utilizing an antisense oligonucleotide (ASO) to inhibit synthesis of the protein. METHODS AND

resultsTo identify molecular signatures and biological pathways associated with AAA, we analyzed RNA sequencing (RNA-seq) data from patients with AAA (GSE57691) and mice with angiotensin II (AngII)-induced AAA (GSE17901) obtained from the GEO database. Transcriptomic analysis revealed a marked upregulation of HMGB1 in both human and mouse aneurysmal tissue. AngII infusion into male LDLR-/- mice significantly increased HMGB1 protein abundance in the abdominal aorta after 7 days consistent with a role in AAA initiation. To assess the functional role of HMGB1 in AAA formation protein synthesis was inhibited using an ASO. Hypercholesterolemia was induced in male mice by expressing PCSK9-D377Y and maintained on a Western diet before being infused with AngII (1000 ng/kg/min) for 4 weeks to induce AAA. Mice (n = 15 per group) received subcutaneous injections of either phosphate-buffered saline or HMGB1 ASO (25 mg/kg/day) on days 0 and 3, followed by weekly injections for the remainder of the study. HMGB1 ASO administration significantly attenuated AngII-induced AAA formation in the absence of any changes in blood pressure.

conclusionsASO-driven HMGB1 inhibition resulted in a profound attenuation of AngII-induced AAA, highlighting its potential as a therapeutic target for AAAs.

Indexed as

Angiotensin IIAorta, AbdominalAortic Aneurysm, AbdominalHMGB1 ProteinOligonucleotides, AntisenseAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutReceptors, LDLAngiotensin IIHMGB1 ProteinHMGB1 protein, humanHMGB1 protein, mouseOligonucleotides, AntisenseReceptors, LDLAngiotensin IIAortic aneurysmsHMGB1

Identifiers

PMID41801895
PMCPMC12972573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.